Investigating how clozapine affects a specific group of patients with schizophrenia
5/5: Selective Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (CLOZAPINE)
This study is looking at how clozapine, a medication for schizophrenia, works best for different groups of patients based on their unique biological traits, so we can help doctors make better treatment choices for those living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11094719 on NIH RePORTER |
What this research studies
This research focuses on understanding how clozapine, an effective antipsychotic medication, can be used to treat patients with schizophrenia who have specific neurobiological characteristics. By utilizing biomarkers to classify patients into distinct subgroups, the study aims to identify which subgroup responds best to clozapine treatment. The research involves analyzing data from a large cohort of individuals with psychosis to determine the relationship between their biological markers and treatment outcomes. This approach seeks to improve diagnostic accuracy and therapeutic decisions for patients suffering from schizophrenia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who exhibit specific biomarker profiles indicating they belong to the B1 subgroup.
Not a fit: Patients who do not have a diagnosis of schizophrenia or those who do not fit into the identified biomarker subgroups may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with schizophrenia, particularly those who are currently unresponsive to standard therapies.
How similar studies have performed: Previous research has shown promise in using biomarker-defined subgroups to tailor treatments for psychiatric conditions, suggesting that this approach may yield beneficial results.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Clementz, Brett a — University of Georgia
- Study coordinator: Clementz, Brett a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.